ESP 01

Drug Profile

ESP 01

Alternative Names: Breast cancer therapeutic - Espera Pharma; ESP-01

Latest Information Update: 20 May 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Esperas Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 13 Apr 2015 Preclinical trials in Solid tumours in Canada (PO)
  • 13 Apr 2015 Esperas plans a phase I trial for Cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top